A comprehensive approach to target screening, hit validation, and binding site determination by nuclear magnetic resonance (NMR) spectroscopy is presented. NMR 19 F signal perturbation was used to screen a small compound library and identify candidate ligands to the target of interest. Ligand dissociation constants were measured using a pegylated form of the protein, which resulted in a 2-fold increase in the strength of the saturation transfer difference signal. The initial small-molecule hits were further optimized by combining a residue-specific labeling strategy, to identify the specific sites of interaction with the protein, with a second site screening approach based on relaxation enhancement using a paramagnetic probe. The advantages of this combination strategy in the identification and optimization of weak binding chemical entities early in a program are illustrated with the discovery of a low micromolar ligand (K d = 20 µM) for Nurr1 and identification of the binding site location through residuespecific 15 N isotope labeling and derivatization of Cys residues with 2-mercaptoethanol-1-13 C. (Journal of Biomolecular Screening 2007:301-311)
INTRODUCTION
N UCLEAR RECEPTORS COMPRISE A LARGE FAMILY of transcription factors that regulate different aspects of cellular development and metabolism. Blocking or activating these molecules may induce desired physiological responses. There has recently been much interest focused on the Nurr1 receptor because it plays an important role in the development of dopaminergic neurons in the midbrain and may represent a therapeutic target to treat Parkinson's disease. 1 The activity of many transcription factors depends on the coregulator protein binding, which in turn is controlled for many nuclear receptors by the binding of small-molecule hormones to a hydrophobic pocket within the ligand-binding domain. Nurr1 lacks this ligand-binding cavity and belongs to the class of orphan nuclear receptors that are constitutively active. 2 In principle, it is conceivable that a small molecule that binds to Nurr1-LBD (subsequently denoted as Nurr1 LBD ) can regulate coregulator binding and increase or decrease the Nurr1 transcriptional efficacy. 3 In an attempt to identify such a small molecule, we produced Nurr1 LBD and used it in affinity screening versus a small (approximately 1000) library of selected organic compounds.
Over the past few years, affinity screening by nuclear magnetic resonance (NMR) has been increasingly used for early lead discovery. A number of different approaches have been developed that rely on signal detection from isotopic 15 N or 13 C, spinlabeled protein, or detection of 1 H or 19 F signals from the small-molecule ligands. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Sensitivity has been a major limiting factor, and so NMR-based screens are usually performed on small (150-1000) rationally designed libraries; 9 screens of libraries as large as 100,000 compounds are feasible if protein supply is not limiting or large pool sizes are employed. 4 The major advantage of NMR-based screening compared to conventional high-throughput screening (HTS) methods is the ability to detect weak ligands, which in the presence of structural information can be rapidly and efficiently developed into higher affinity leads. 14 One example is the design and discovery of high-affinity ligands for PTP-1B, 15 where traditional HTS approaches were not successful.
Here we present an integrated NMR approach to lead generation for the target Nurr1. An initial affinity screen of a small compound collection using 19 F NMR was used to identify an initial set of ligands. The binding affinities were further improved through secondary screens using 1 H NMR and spin labeling, and the location of the ligand-binding site was determined by heteronuclear NMR. We also describe the construction of a 19 Flabeled compound library and the 19 F NMR screening methodology using a flow probe. Follow-up on the original hits was performed by 1 H NMR magnetization transfer experiments, designed for accurate determination of dissociation constants. Here, to improve the sensitivity of these experiments, we augmented the effective molecular weight of Nurr1 by N-terminal pegylation. A molecule showing a 5-fold improvement (5 in Table 1 ) in binding affinity over the original 100-µM hit (1 in Table 1 ), identified from 19 F NMR screening of a small compound library, was achieved by second-site NMR screening with a spin-labeled analog 16 (2 in Table 1 ). The same spin-labeled compound was also used in conjunction with isotopic labeling of the Nurr1 LBD to locate the ligand-binding site using the X-ray coordinates of apo Nurr1 LBD .
MATERIALS AND METHODS

Preparation of Nurr1 LBD and Nurr1 LBD -C566S mutant
Residues 362-598 of human Nurr1 LBD were cloned into a proprietary vector containing an N-terminal affinity tag. The protein was expressed in Escherichia coli cells and fermented in terrific broth at 30 °C. Induction occurred at 8.0 OD 600 for 6 h, and cells were harvested at final 35.0 OD 600 . The cell pellet was resuspended in a lysis buffer containing 10 mM imidazole (pH 7.5), 400 mM NaCl, 4 mM β-mercatopethanol, 0.5% 1,2-propanediol, and 1 mM CHAPS. The cells were lysed by sonication and centrifuged at 48,000 g for 1 h. The cell lysate was loaded onto HisBind resin (Novagen, Madison, WI) and washed with 5 column volumes of lysis buffer containing 4 mM adenosine triphosphate (ATP) and 10 mM MgCl 2 . The affinitytagged Nurr1 LBD was eluted with a 10-to 200-mM imidazole (pH 7.5) gradient containing 4 mM β-mercatopethanol and 0.5% 1,2-propanediol. The pooled fractions were further purified by anion exchange and then loaded onto a POROS HQ 20 (Applied Biosystems, Foster City, CA) column equilibrated in 20 mM 4(2-hydroxyethyl)-piperazine-ethane-sulfonic acid (HEPES, pH 8.0), 20 mM β-mercatopethanol, and 1 mM EDTA. Following 5 column volumes of a wash step, the protein was eluted with 0 to 500 mM NaCl gradient. Pooled fractions were concentrated using an Amicon-stirred cell 10K Da molecular weight cutoff (Millipore, Billerica, MA) and loaded onto a Superdex 200 (GE Healthcare, Buckinghamshire, UK) gel filtration column in buffer containing 20 mM HEPES (pH 8.0), 20 mM β-mercatopethanol, and 100 mM NaCl (storage buffer).
The C566S mutant was cloned, expressed, and purified in a manner similar to that of native Nurr1 LBD , except as follows. Cells containing mutant construct were grown overnight in 1 L terrific broth/2.8 L Fernbach flask to 0.5 to 0.8 OD 600 , then induced for 5 h to 2.0 OD 600 . Small-scale purification was performed using affinity chromatography by 5 mL HiTrap Chelating HP, followed by 5 mL HiTrap Q FF anion exchange and Superdex 75 gel filtration (Amersham Biosciences, Pittsburgh, PA). (1) and Follow-up Compounds Discussed in the Text
The K d values were obtained from differential saturation transfer difference (dSTD) experiments. 15 N-labeled amino acids (CIL, Andover, MA), with any remaining amino acids added in their unlabeled form (Sigma, St. Louis, MO). Nurr1 expression was directed from 10 to 12 µg/mL recombinant pIVEX 2.3 MCS DNA incorporating the gene for an N-terminally affinity-tagged Nurr-1 LBD (residues 362-598). Reactions were incubated in the RTS Proteomaster instrument at 900 rpm and 30 °C for 20 h. Samples for analysis were acetone precipitated prior to SDS-PAGE electrophoresis. The remaining extract from the reaction chamber was then harvested. The extract was first digested with 20 U/mL each of RNAase and DNAase (Roche) for 15 min at room temperature and then microfuged 8 min at 14,000 rpm and 4 °C. The resulting supernatant was collected for purification.
Samples were produced at either the 1-or 10-mL scale. Each sample was diluted 10-fold with the lysis buffer described earlier and loaded onto an Akta Explorer equipped with serial 5-mL HiTrap Chelating HP followed by 5-mL HiTrap Q FF anion exchange columns. The sample was washed with 5 column volumes of buffer before being eluted with an imidazole buffer onto the anion exchange column. The column was again washed with 5 column volumes before being eluted with an NaCl gradient as described earlier. Fractions from this final column were pooled, washed with storage buffer, and then concentrated using 20-kDa cutoff Vivaspin concentrators. Samples were produced that contained 15 N-labeled leucine, phenylalanine, and serine.
Pegylation of Nurr1 LBD . Nurr1 LBD was conjugated with methoxy polyethylene aldehyde (molecular weight 20 kDa) in HEPES buffer, pH 7.5, in the presence of cyanoborohydride as a Schiff base. The reaction mixture was incubated and stirred overnight at 4 °C. Different Nurr1 LBD -PEG conjugates were separated using a HiTrap Sepharose Q column (Pharmacia, Kalamazoo, MI). All fractions were pooled and characterized by N-terminal amino acid sequencing analysis. The yield of N-terminal monopegylated Nurr1 LBD was 40%.
Preparation of Nurr1 LBD derivatized with 2-mercaptoethanol-1-13 C. The Nurr1 LBD was exchanged from the storage buffer into 20 mM HEPES, 5 mM DTT, and 100 mM NaCl buffer followed by exchange into 20 mM HEPES, 100 mM NaCl buffer containing 5 mM of OH-13 CH 2 -CH 2 -S-S-CH 2 -13 CH 2 -OH (obtained by oxidation of 2-mercaptoethanol-1-13 C from Isotec, Miamisburg, OH). Finally, the solution was exchanged into 20 mM HEPES-d 18 (CIL), 100 mM NaCl buffer (100% D 2 O) at pH 7.7. This solution was purged with argon, and the final concentration of the Cys-derivatized Nurr1 LBD was 200 µM.
Spectrophotometric measurements. All Nurr1 LBD concentrations were determined with a NanoDrop ND-100 Spectrophotometer using 0.71 AU for absorption of 1 mg/mL at 280 nm. The protein hydrodynamic size measurements were performed with a size exclusion chromatography/laser light-scattering (SEC/LS) system consisting of an Agilent 1100 high-pressure liquid chromatography system and Wyatt miniDawn/QELS laser light-scattering detector. The running buffer was phosphate-buffered saline (PBS).
Synthesis of compounds 2-5. 4-[1-(4-Fluoro-benzyl)-1H
benzoimidazol-2-ylamino]-2,2,6,6-tetramethyl-piperidin-1-oxyl radical (2) was prepared via N-alkylation of 2-chlorobenzimidazole with 4-fluorobenzylchloride and sodium hydride in dimethylformamide (DMF), which was then heated with 2,2,6,6-tetramethylpiperidin-4-ylamine at 200 °C to give [1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine. The piperdine intermediate was dissolved in water-acetone and treated with K 2 CO 3 , H 2 O 2 , Na 2 WO 4 , and EDTA according to a literature method 17 to afford 4-[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-ylamino]-2,2,6,6-tetramethyl-piperidin-1-oxyl radical following workup and purification. The N-hydroxide (3) was prepared by dissolving 2 in ethanol and adding 5-fold excess of hydrochloric acid in ether followed by solvent evaporation. 4- (5) were prepared as previously described. 18
F library construction
Approximately 5000 compounds (both from in-house and commercial sources) containing 1 or more 19 F atoms, of a molecular weight between 200 and 500 D and chemically stable in aqueous solutions, were initially selected. These compounds were screened at a 200-µM concentration for solubility in PBS buffer, using 19 F flow NMR. Compounds that were not fully soluble (equal to or above 0.5 × nominal concentration) were labeled as poorly soluble but included in the library. A final set of 1000 compounds was pooled in groups of 8 to 10 to optimize 19 F signal dispersion and structural dissimilarity while minimizing the number of poorly soluble compounds in a given pool. A 6-µL aliquot of each pool in DMSO-d 6 was dispensed into 250-µL, conical-bottom 96-well plates and stored at -80 °C for subsequent use. The screening concentrations in an individual pool were 50 µM and 30 µM per compound with F or CF 3 substituents, respectively.
NMR spectroscopy
The 19 F NMR screening was performed on a Bruker DRX500 spectrometer using a Nalorac 120-µM dual 19 F, 1 H flow probe. A slightly modified Bruker BEST system with no sample recovery was used for liquid handling. To each well containing a 19 F pool, 200 µL of Nurr1 buffer (50 mM HEPES, 100 mM NaCl, 2 mM Tris(2-crboxyethyl)-phosphine hydrochloride [TCEP], pH 7.7) was added and the plates sealed with aluminum foil to prevent water evaporation during the time course of a screen (4 days).
Discovery of Ligands for Nurr1 by NMR Screening
One of 2 duplicated wells contained 50 µM of Nurr1 LBD protein. 19 F { 1 H-decoupled} NMR spectra for each well were obtained using the standard Bruker pulse library program with a total accumulation time of 25 min. The dead time delay, DE, was increased to 150 µs to avoid baseline roll from the broad 19 F background signal. The first-order phase correction was calculated according to the following formula:
where DW is the acquisition dwell time.
NMR samples for competitive saturation transfer difference (cSTD) and differential saturation transfer difference (dSTD) experiments were prepared in 95% D 2 O/5% H 2 O deuterated Nurr1 buffer (50 mM HEPES-d 18 , 2 mM TCEP-d 16 from CIL, 100 mM NaCl, pH 7.7) and measured on a Bruker DRX500 spectrometer equipped with a TXI cryoprobe. Protein concentrations were either 3 µM for Nurr1 LBD or 1 µM for Nurr1 LBD -PEG. All spectra were recorded in direct difference mode: 1 scan with CW presaturation (¥B 1 = 50 Hz, 3.5 s irradiation time) at 0.6 ppm and 1 scan with the same CW field at -10 ppm (off-resonance) with the concomitant inversion of receiver phase and a total acquisition time of 1 h. Residual HDO signal was suppressed with an excitation sculpting pulse train. 19 Second-site screening was performed by comparing 1D 1 H NMR spectra obtained in the presence of the spin-labeled compound 2 versus spectra obtained in the presence of its cold analog 3 ( Table 1) . Samples were prepared in 100% D 2 O containing deuterated Nurr1 buffer, 30 µM fully deuterated 15 N, 2 H-labeled Nurr1 (Nurr1 LBD -ND), 100 µM 2 or 3, and 500 µM of a secondary ligand.
For 15 N-1 H heteronuclear single-quantum correlation spectroscopy (HSQC) and transverse relaxation-optimized spectroscopy (TROSY), spectra samples were prepared in 95% H 2 O/5% D 2 O deuterated Nurr1 buffer at pH 7.7. 20, 21 Typically, 35 to 50 µM of Nurr1 LBD -ND protein was used in these measurements. For binding site determination, spectra were recorded in the presence of a 20-µM compound (2 or 3) using standard Bruker pulse sequences. Hypercomplex 128 × 2048 data points were acquired per spectrum with acquisition times of 42.1 ms and 102.5 ms in the t 1 and t 2 dimensions, respectively. For 13 C-1 H HSQC spectra, 32 × 1024 complex data points were collected with acquisition times of 25.4 ms and 170.5 ms in the t 1 and t 2 dimensions, respectively. For 1 H-1 H nuclear Overhauser enhancement spectroscopy (NOESY) spectra, 256 × 2048 complex data points were collected with acquisition times of 21.3 ms and 170.5 ms in the t 1 and t 2 dimensions, respectively. Protein samples were prepared in 100% D 2 O containing Nurr1 LBD -ND buffer at pH 7.7.
Calculations of dissociation constants
The dissociation constant values from saturation transfer difference (STD) experiments were calculated iteratively from the dSTD(c 1 ,c 2 ) values ( Fig. 1) and numerical solutions of the coupled differential equations for a 3-spin system: ABC = BC + A, where A, B are free and bound ligand spins, respectively, and C is the irradiated protein spin (usually methyl group). 22 Simulations of magnetization transfer in the 3-spin case for different relaxation and chemical exchange rates showed that, to a good approximation, the ratio of relative magnetization transfer intensities obtained from STD measurements at 2 different ligand concentrations, dSTD(c 1 ,c 2 ) in the limit of [P t ] << c 1 , depends essentially only on the value of the K d (Fig. 1) . Typically, c 1 = 50 µM, c 2 = 100 µM for stronger and usually less soluble ligands ( (1). STD, saturation transfer difference; dSTD, differential saturation transfer difference.
To assess accuracy of the dSTD method, we measured a wide range (10-1200 µM) of K d values for binding of small molecules to human serum albumin (HSA; data not shown) and found excellent agreement with the published literature values. 23 The K I values from cSTD experiments were obtained by measuring saturation transfer intensities for a probe, in the presence (STD 1 ) and absence (STD 0 ) of an inhibitor, and fitting these data to the following equation: 24 where [P t ], [L t ] are total concentrations of the protein and the probe, respectively, and K d is the dissociation constant for the probe.
[P] I is the effective protein concentration in the presence of an inhibitor and is expressed by the following equation:
where [I t ] is the total inhibitor concentration and K I is the inhibition constant of the saturation transfer effect; K I equals dissociation constant only when the probe and the inhibitor are binding to the same binding site.
The K d values from HSQC titrations were obtained by fitting the following equation:
where ν obs , ν F , ν B are chemical shifts of a protein resonance in partially saturated, free, and fully saturated forms of the protein. The above equation was only used in the fast chemical exchange limit: k off >> ν B -ν F .
Binding site determination
The binding site calculations were performed by imposing a 3D grid with 1Å resolution onto the pdb coordinates of the apo Nurr1 LBD structure and then conducting an iterative search of all grid points fulfilling the given distance constraints obtained from the NMR measurements.
All computations were performed in Matlab 7.0.4 command language on a PC computer.
RESULTS
F NMR screen and hit validation
A library of approximately 1000 compounds was screened by 19 F flow NMR against Nurr1 LBD . The data were visually inspected by comparing spectra from 2 adjacent wells: 1 with and 1 without the protein. Only 25 19 F resonances showed significant line perturbations in pools with protein present. More than 60% of the observed spectral changes seen in the pools were confirmed by recording 19 F spectra of individual compounds ± Nurr1 LBD . K d values for the individually confirmed hits were determined from the dSTD experiments, where only 4 compounds showed values less then 500 µM. Figure 2 shows a pool that gave 1 hit (1 in Table 1 ). Only the 19 F signal for this compound is significantly broadened (3-fold) in the spectrum of the pool with the protein as compared to the spectrum of the pool without the protein.
Remaining signals from other compounds in this pool remain unchanged upon the addition of protein. Compound 1 showed the lowest K d of 100 µM in the dSTD experiment ( Fig. 3) . Binding of 1 was also confirmed by 15 N-1 H HSQC titrations, where a number of peaks shifted upon addition of the compound. In the titration series, the chemical shift perturbations separated into 2 distinct groups. For the first and larger set of peaks (14 residues) showing significant chemical shift perturbations (up to 0.2 ppm and 2 ppm in the 1 H and 15 N dimensions, respectively), K d values in the range of 100 to 300 µM were obtained. The second, smaller group (4 residues) showed chemical shift changes corresponding to a much weaker binding interaction, with K d values in the range 1000 to 2000 µM. This heterogeneous titration pattern could be explained either by different orientations of the ligand within the same binding site and/or by binding of the ligand to more than 1 discrete site on the protein. In either case, the differences give rise to a measurable difference in the binding affinity of the ligand to the protein, as observed in the protein chemical shift perturbation titration experiment. At this point, we did not make any effort to assign the protein NH resonances perturbed on small-molecule binding because ca. 40% of the expected NH peaks were missing in 15 N-1 H TROSY spectra of both apo and complexed (with 1) forms of Nurr1 LBD -ND. This indicates that the protein is in a conformationally mobile state, which seems to be a general phenomenon for apo ligand-binding domains of nuclear hormone receptors. 25, 26 
STD experiments
Saturation transfer experiments used in this work rely on transferring spin polarization between 2 molecules during short periods (< 1 s) of contact in solution, and only the spin system of 1 molecule (protein) is perturbed by the radio frequency field.
Discovery of Ligands for Nurr1 by NMR Screening
Journal of Biomolecular Screening 12(3); 2007 www.sbsonline.org 305 (2) (3) (4)
The observed signal (STD) corresponds to the saturated population of the ligand, where the degree of saturation depends on many kinetic and dynamic parameters of the system (experimental section). The STD experiments require the least amount of protein to observe ligand binding as compared to other NMRbased methods (e.g., HSQC), but they are only suitable for the detection of weak ligands (k off >> 1 s -1 ). The magnitude of the STD signal strongly depends on the correlation time for the overall tumbling of the molecule, 22 which, according to Stokes's equation, is directly proportional to the hydrodynamic size of a protein and solvent viscosity and inversely proportional to temperature. Because Nurr1 LBD is a relatively small protein (molecular weight 27.5 kD), we produced a pegylated version of the molecule (20-kD PEG attached to the N-terminal methionine), which gave a significantly stronger (approximately 2-fold) STD signal for 1 and other ligands found in the 19 F screen. The increase in signal strength translates into a 4-fold decrease in the acquisition time, as compared to experiments using a nonpegylated version of the protein. This results in better data quality and enables testing of higher affinity ligands (0.1 µM ≤ K I < 1 µM) using cSTD experiments. Interestingly, dynamic light-scattering measurements showed a more pronounced difference in the hydrodynamic radii of the 2 forms of the protein: 34 Å versus 60 Å for Nurr1 LBD and PEG-Nurr1 LBD , respectively. These observations suggest that the conjugate retains a substantial degree of internal mobility. To further improve the sensitivity, all STD experiments were recorded at 281 K for the purpose of increased viscosity.
Saturation transfer experiments were used primarily to screen our sample collection for compounds similar to 1 and preserving the benzimidazole core, defined as the chemistry scaffold for the initial ligand series identified in the 19 F screen. This allowed a rapid exploration of the chemical space around the best hit from the primary screen with very low protein consumption (less then 30 µg of PEG-Nurr1 LBD per single STD experiment) and without the need for 19 F labeling of the small molecules. 2-Amino benzimidazole alone showed a K d ≥ 2 mM, and substitutions of its benzene ring or substitutions at position 2, other than a primary or secondary amine, completely abrogated the binding. Interestingly, the benzyl group in 1 seems to be quite conserved, with loss of affinity upon an increase of the size of the substituent in the para position (K d values of 150 µM, 300 µM, 500 µM, and > 1000 µM were measured for compounds with no, Cl, CH 3 , and C(CH 3 ) 3 para substituents in 1-benzyl, 2-amino benzimidazole, respectively). Overall, more than 100 analogs of compound 1 from our in-house sample collection were screened against Nurr1 LBD with no improvement over the 100-µM affinity of the original hit. Because no compounds with an N-substituted piperidine ring of 1 were readily available, we used the secondsite screening approach to look for potential fragments for linking at this site. 16 
Second-site screening
Second-site screening proved to be extremely useful in the lead optimization process. 15 This approach relies on finding 2 ligands that bind to separate sites of the same target but are proximal enough so that tethering can produce the desired increase in affinity. Originally proposed by Jahnke et al., 6 the method relies on looking for spectral changes (usually line broadening) from small molecular fragments when measured in the presence of a protein and spin-labeled molecule. We adopted this strategy for compound 1, where replacement of the piperidinyl moiety by 2,2,6,6-tetramethyl-piperidin-1-oxyl radical (TEMPO; compound 2 in Table 1 ) provided the most straightforward approach. It was confirmed that the affinities of 2 and its cold analog 3 to Nurr1 LBD are the same as for parent 1 (100 µM), as measured by the cSTD experiment with 1-parachlorobenzyl, 2-amino benzimidazole (K d = 300 µM) as the probe. For second-site screening, we used a small collection of 50 mono-and di-substituted toluenes. Spin simulations for weakly binding ligands (K d = 5 mM) performed under the same conditions as used in the screen indicated more than 20% signal attenuation for protons that bind at distance less then 5 Å to the radical (data not shown). In the secondary screen, p-cresol showed the most pronounced line broadening with ~30% reduction of the methyl group signal intensity. The interligand nuclear Overhauser (NOE) connectivity was subsequently demonstrated using the 2D transferred NOESY (tr-NOESY) experiment ( Fig. 4) . 27 To achieve optimal efficiency for the intermolecular magnetization transfer between p-cresol and compound 3, fully deuterated Nurr1 LBB -ND was used in this experiment. The spectrum in Figure 4 contains only positive, transferred NOE cross-peaks between protons of the same molecule plus interligand cross-peaks from the methyl protons of 3 to all protons from p-cresol. Because only the methyl signal was significantly reduced in the presence of the spin label, magnetization transfer to the ring protons is most likely the result of spin diffusion. The control experiment with no protein showed only weak and negative intraligand cross-peaks. Based on these data, a chemical synthesis strategy was developed that would generate a link between the 2 fragments via the nitrogen of the piperidine moiety using simple chemistry: 1 with methylene (compound 4 in Table 1 ) and 1 with ethylene (compound 5 in Table 1 ) linkers between the piperidine ring and the hydroxyphenyl group. Tethering the 2 fragments with the ethylene linker resulted in a 5-fold improvement in affinity. The K d values were obtained from dSTD, 15 N-1 H HSQC titration, and cSTD experiments ( Fig. 5) . Compound 4 showed a K d = 130 µM in the dSTD experiment. These data clearly demonstrate that the length of the linker is critical for the affinity of the tethered ligand.
Binding site determination
Efforts to obtain crystals of Nurr1 LBD with compounds 1 and 5 were not successful, likely due to the limited solubility of the ligands. Binding site determination for weak ligands can also be obtained by following 15 N-1 H chemical shift changes upon complex formation. 28 However, this approach could not be used because of the incomplete nature of the apo-Nurr1 LBD HSQC spectrum, due to the protein conformational mobility in the nonliganded state, which prevented a full resonance assignment. 25, 26 Here we describe another approach that combines site-specific/residue-specific isotope labeling with relaxation enhancement, using a paramagnetic ligand, to obtain structural information on the binding site in a protein small-molecule complex.
We recorded 15 N-1 H TROSY spectra of Nurr1 LBD -ND in the presence of hot (2) and cold (3) ligands. Signals from nuclei separated by less than 10 Å from the binding site of the radical experience paramagnetic relaxation enhancement, which results in a loss of signal intensity in the NMR spectra. The most pronounced changes are shown in Figure 6A for serine and leucine resonances, which were assigned using selectively labeled samples; assignments were based on 15 N-1 H HSQC spectra of Nurr1 LBD specifically labeled by 15 N at these amino acid types. Figure 6A also shows paramagnetic signal attenuation for a Hε/δ proton of histidine assigned on the basis of the 15 N chemical shift (250 ppm). The most essential piece of information was obtained with chemically derivatized Nurr1 LBD , where 3 of 5 cysteine residues were readily alkylated using 2-mercaptoethanol-1- 13 C. The 13 C-1 H HSQC spectra recorded in the presence of the hot (2) and cold (3) ligands (Fig. 6B) indicate that the side chain of 1 cysteine, for which the 13 C-1 H correlation disappears in the presence of (2), must be close to the ligand-binding site. This cysteine was assigned by subsequent expression and derivatization of the C566S mutant protein, for which the 13 C-1 H correlation of interest was shown to be missing. The 4 distance constraints, 2 to 8 Å between TEMPO and {Ser-NH, Ile-NH, His-Hδ} and 2 to 10 Å between TEMPO and the sulfur atom of Cys556, were used to determine the binding site within the crystallographic coordinates of the Nurr1 LBD . The upper bounds of these constraints were estimated based on the amount of signal attenuation and theoretical simulation for the fast chemical exchange limit. 29 The binding site is shown as the sphere in Figure 7 , which encompasses a relatively small space between helices 4, 11, and 12 and is reminiscent of the coregulator binding site found in other known nuclear receptors.
DISCUSSION
In this study, we have presented a strategy where library screening, hit validation, and affinity improvement were achieved entirely through the use of high-resolution NMR methods. Only 1000 compounds were initially screened, using approximately 20 mg of the protein, after which secondary screening in the presence of spin-labeled ligand led to the synthesis of compound 5 with a dissociation constant in the low micromolar range. In contrast, other non-NMR affinity-based high-throughput screens for Nurr1 LBD , performed on up to 4,000,000 compounds, delivered only a couple of hits in the K d range (5 µM) and none below 1 µM.
Screening by 19 F NMR is a good compromise between the cost of protein labeling, sensitivity, and pool deconvolution. Strong ligands (k off < 1 s -1 ) are detectable, which may be easily missed in other NMR-based screens based on ligand detection. Molecules containing 19 F are freely available, and construction of a diverse screening library with a large number of drug-like molecules is straightforward. Newer 19 F cryo-probe technology, not implemented for this work, should significantly decrease protein consumption or increase screening throughput. Different isotope and spin-labeling strategies in conjunction with the apo crystal structure allowed determination of the binding site in a rapid fashion. Although detailed modeling of the complex structure was not practical, the binding site information was essential to assess the relevance of ligand binding.
Screening based on magnetization transfer requires the least amount of protein, but it is limited by the molecular size of a target. We chose 1 out of several possibilities to overcome this limitation by attaching a 20-kD PEG fragment to the N-terminus of Nurr1 LBD . Other choices, such as the commonly used glutathione S-transferase (GST) fusion partner, suffer from the disadvantage that the partner may bind the weaker ligands themselves and thus complicate interpretation of the STD spectra. Increasing buffer viscosity is only practical to the point where it does not degrade the intensity of the NMR signals from a free ligand. Pegylation of the target therefore seems to offer a good compromise. This was especially in our case, where it also increased the stability of the truncated Nurr1 protein, which otherwise has a high propensity to partially unfold, aggregate, and ultimately precipitate during long periods at room temperature or during long-term storage at 4 °C. Finally, the use of low protein concentrations (1 µM) in terms of NMR applications 30 minimizes nonspecific binding and smallmolecule aggregation propensity. This gives more accurate estimations of dissociation constants from dSTD experiments and, in cSTD experiments, allows one to accurately measure dissociation constants down to 100 nM, important during the later stages of lead optimization.
When working with relatively weak ligands, the cocrystal structure is usually not available, and it is often not feasible to solve the full structure of these types of complexes by NMR. The lack of structural information may also be compounded by the absence of a natural ligand with a known mechanism of binding. In our case, determination of the small-molecule binding site in the complex with protein, shown in Figure 7 , was achieved in a rapid fashion by combination of amino acid type selective labeling, chemical derivatization of the protein, and spin labeling of the ligand. Although this approach depends on the availability of an apo crystal structure, it may also prove to be useful in facilitating the analysis of X-ray data obtained from soaking apo crystals in the presence of weakly binding ligands. The strategy presented in this article is particularly suited for finding weak but structurally relevant ligands to orphan targets or protein-protein interactions that are problematic for HTS screens (e.g., no competitive ligand for displacement assay). Such ligands can be further optimized to more potent drug candidates by using medicinal chemistry resources and structurebased drug design methods.
FIG. 7.
The binding site (sphere) of the 2,2,6,6-tetramethyl-piperidin-1-oxyl radical (TEMPO) moiety from 2 within the 3D structure of Nurr1 LBD . The calculations were based on in-house generated X-ray structure of Nurr1 LBD (Christopher Mohr, unpublished data) and nuclear magnetic resonance-derived distance constraints: 2 to 8 Å between TEMPO and {Ser-NH, Ile-NH, His-Hδ) and 2 to 10 Å between TEMPO and the Cys556 sulfur atom.
